Related Experiment Video
Updated: Aug 23, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Novel therapeutics in the treatment of bladder cancer
Jay B Shah1, James M McKiernan
1Department of Urology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA.
Purpose Of Review:
The successful treatment of bladder cancer remains a challenge for urologists and oncologists. There have been substantial changes in the therapeutic options for the management of both superficial and muscle-invasive bladder cancer in the last 5 years. Here we review the preclinical and clinical developments over the last year in bladder cancer therapeutics.
Recent Findings:
There is a growing trend toward the use of multimodal treatments for all bladder cancers. For superficial disease, intravesical instillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard of care. Novel therapeutic modalities under investigation include DNA vaccines, magnetically targeted carriers, bio-adhesive microspheres and antisense oligodeoxynucleotides. For muscle-invasive bladder cancer, systemic perioperative chemotherapy is being used with increasing frequency and the latest preclinical research efforts are focused on the inhibition of angiogenesis and other processes predisposing to metastatic disease.
Summary:
Treatment goals for bladder cancer of any stage are complete removal of the initial tumor, prevention of disease recurrence and effective inhibition of progression to advanced disease with the ultimate aim of reducing mortality. The myriad novel therapeutic modalities currently being explored suggest that these goals may perhaps be achievable within our lifetime.
Insights
Recent advancements in bladder cancer treatment focus on multimodal strategies for both superficial and muscle-invasive disease. Novel therapies, including intravesical instillations and systemic chemotherapy, show promise in preventing recurrence and reducing mortality.
Area of Science:
- Urology
- Oncology
- Cancer Therapeutics
Background:
- Bladder cancer treatment presents ongoing challenges for clinicians.
- Significant therapeutic advancements have emerged in the last five years for both superficial and muscle-invasive bladder cancer.
- This review focuses on preclinical and clinical developments in bladder cancer therapeutics over the past year.
Purpose of the Study:
- To review recent preclinical and clinical developments in bladder cancer therapeutics.
- To highlight evolving treatment strategies for superficial and muscle-invasive bladder cancer.
- To discuss novel therapeutic modalities under investigation.
Main Methods:
- Review of preclinical research.
- Analysis of clinical trial data.
- Synthesis of recent therapeutic developments in bladder cancer.
Main Results:
- Multimodal treatment approaches are increasingly adopted for all bladder cancer stages.
- Intravesical chemotherapy post-transurethral resection is becoming standard for superficial bladder cancer.
- Systemic perioperative chemotherapy is more frequent for muscle-invasive bladder cancer, with research targeting angiogenesis and metastasis.
Conclusions:
- Key treatment goals include complete tumor removal, recurrence prevention, and inhibiting progression to advanced disease.
- Novel therapeutic modalities show potential for achieving these goals and reducing bladder cancer mortality.
- The future of bladder cancer management may involve achieving these ambitious treatment objectives.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...